PILOT AND FEASIBILITY PROGRAM The C-SiG Pilot and Feasibility (P/F) Program is vital for helping us attract new investigators to digestive disease research. The P/F Program provides investigators with sufficient funds to obtain robust preliminary data to be used in research grant applications awarded by external agencies, especially NIDDK. In addition to research funding, P/F awardees are mentored by the C-SiG Leadership and are provided career development opportunities through the C-SiG Enrichment Program. Thus, the P/F program allows C-SiG to foster and strengthen the pipeline of new investigators engaging in digestive disease research. The primary goal of the C-SiG P/F Program is to support new investigators (Type N) just beginning their careers in digestive diseases research. Proposals are also accepted from established, funded investigators who are new to digestive disease research (Type EN) who wish to test the applicability of their expertise to a digestive disease-related problem. The P/F Program typically funds up to four outstanding proposals each year for a total of $100,000 per year. Since 2009 when C-SiG began, the P/F Program has received an average of 9 applications each year, and funded 26 investigators (25 Type N ,1 Type EN, 0 Type E) with first year awards ranging from $25,000-$40,000 (average award $30,000) in direct annual costs per year. Additionally, P/F recipients are eligible to compete for a New Supported Investigator Award that provides a second year of funding (up to $50,000) to one P/F Award recipient who has made exceptional progress during their first year. Since 2009 when C-SiG began, 7 Named Supported Investigator Awards have been given to meritorious P/F projects to provide a second year of funding (average award $39,000 per year [range $20,000-50,000; total $275,000] provided by Mayo). As of May 2018, 19/26 (73%) P/F award recipients have achieved independent Federal funding. A detailed and rigorous peer review process has been developed to select projects of the highest quality. Built in this process is a mechanism to provide detailed constructive criticism to all eligible applicants, including the unfunded ones. The following sections detail the eligibility requirements, the mechanisms used to announce program funds, the application process and mechanisms for scientific review, and the mechanisms for program oversight and review.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK084567-12
Application #
9969417
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
12
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Mouchli, Mohamad A; Singh, Siddharth; Boardman, Lisa et al. (2018) Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. Inflamm Bowel Dis 24:1074-1081
Paradise, Brooke D; Barham, Whitney; Fernandez-Zapico, Martín E (2018) Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes? Cancers (Basel) 10:
Banales, Jesus M; Marzioni, Marco; LaRusso, Nicholas F et al. (2018) Cholangiocytes in health and disease: From basic science to novel treatments. Biochim Biophys Acta Mol Basis Dis 1864:1217-1219
Tarragó, Mariana G; Chini, Claudia C S; Kanamori, Karina S et al. (2018) A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab 27:1081-1095.e10
Kim, Minsoo; Druliner, Brooke R; Vasmatzis, Nikolaos et al. (2018) Inferring modes of evolution from colorectal cancer with residual polyp of origin. Oncotarget 9:6780-6792
Druliner, Brooke R; Wang, Panwen; Bae, Taejeong et al. (2018) Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. Sci Rep 8:3161
Mansini, Adrian P; Lorenzo Pisarello, Maria J; Thelen, Kristen M et al. (2018) MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma. Hepatology 68:561-573
Moncsek, Anja; Al-Suraih, Mohammed S; Trussoni, Christy E et al. (2018) Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice. Hepatology 67:247-259
Allen, Alina M; Shah, Vijay H; Therneau, Terry M et al. (2018) The role of 3D-MRE in the diagnosis of NASH in obese patients undergoing bariatric surgery. Hepatology :
Dhanasekaran, Renumathy; Nault, Jean-Charles; Roberts, Lewis R et al. (2018) Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology :

Showing the most recent 10 out of 537 publications